New therapy eradicates cancer cells without targeting healthy ones.Byline: ANI Washington, Nov 5 (ANI): Researchers are close to developing a cancer treatment that kills malignant cells whilst leaving healthy cells untouched. Led by Professor Cohen-Armon of Tel-Aviv University, the researchers found that potent phenanthridine phenanthridium, phenanthridine a group of chemotherapeutic agents used in the treatment of trypanosomiasis. Includes isometamidium, homidium, pyrithidium (Prothidium) and quinapyramine. derived polyADP-ribose polymerase (PARP PARP Poly ADP-Ribose Polymerase PARP Planning And Review Process PARP PfP Planning and Review Process (NATO) PARP Pajarito Archaeological Research Project PARP Possible Acknowledgement Returning Period PARP Proxy Attribute Request Protocol ) inhibitors efficiently eradicate MCF-7 and MDA (1) (Monochrome Display Adapter) The first IBM PC monochrome video display standard for text. Due to its lack of graphics, MDA cards were often replaced with Hercules cards, which provided both text and graphics. See PC display modes and Hercules Graphics. 231 breast cancer cells without impairing normal proliferating cells, such as human epithelial cells Epithelial cells Cells that form a thin surface coating on the outside of a body structure. Mentioned in: Corneal Transplantation (MCF-10A), nor normal non-proliferating cells, such as neurons and cardiomyocytes. PARP inhibitors were originally designed to protect cells from cell-death under stress conditions (e.g. stroke or inflammation). The researchers examined human cancers depending on a constitutive activity of externally regulated kinase (ERK ERK Extracellular Signal-Regulated Kinase ERK Electronic Records Keeping ERK Externally Regulated Kinases ). The rationale for testing PARP inhibitors in these cancers was the recently disclosed up-regulation of ERK signals in the nucleus by activated PARP-1. However, there are other mechanisms that also come into play. The phenanthridine PJ-34 caused a permanent G2/M cell-cycle arrest and cell death within 48-72 hours in breast cancer MCF-7 and MDA231 cells. On the other hand, normal proliferating cells overcame the imposed G2/M cell-cycle arrest within 12 hours, survived and continued to proliferate. In the lab, PJ-34 prevented the development of MCF-7 and MDA231 xenotransplants in nude mice without affecting their growth, development or behaviour. Other PARP inhibitors were recently proved efficient only for treating relatively rare hereditary human cancers developed in individuals with an impaired DNA repair (BRCA gene mutation). However, in the current research, breast cancer cells lacking the BRCA BRCA One of two genes (designated BRCA1 and BRCA2) that help repair damage to DNA, but when inherited in a defective state increase the risk of breast and ovarian cancer. mutation were efficiently eradicated. "This research provides a new therapeutic approach for a selective eradication of abundant human cancers," said Professor Cohen-Armon. The study has been published in BioMed Central's open access journal Breast Cancer Research. (ANI) Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion